|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1994-4-5
|
|
pubmed:abstractText |
The hematopoietic growth factor P-100 is a monocyte-colony stimulating factor purified from human urine and has been reported to reduce neutropenia following chemotherapy. In this study the effect and toxicity of P-100 was evaluated in 26 patients receiving intensive chemotherapy for SCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
877-81
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8117608-Adult,
pubmed-meshheading:8117608-Aged,
pubmed-meshheading:8117608-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8117608-Carboplatin,
pubmed-meshheading:8117608-Carcinoma, Small Cell,
pubmed-meshheading:8117608-Etoposide,
pubmed-meshheading:8117608-Female,
pubmed-meshheading:8117608-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:8117608-Humans,
pubmed-meshheading:8117608-Lung Neoplasms,
pubmed-meshheading:8117608-Male,
pubmed-meshheading:8117608-Middle Aged,
pubmed-meshheading:8117608-Neoplasm Recurrence, Local,
pubmed-meshheading:8117608-Remission Induction,
pubmed-meshheading:8117608-Survival Rate,
pubmed-meshheading:8117608-Treatment Outcome
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC).
|
|
pubmed:affiliation |
CRC Dept Medical Oncology, Christie Hospital, Manchester, U.K.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
